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ABSTRACT
Objective: To examine the comparative efficacy and
safety of antithrombotic treatments (apixaban,
dabigatran, edoxaban, rivaroxaban and vitamin K
antagonists (VKA) at a standard adjusted dose (target
international normalised ratio 2.0–3.0), acetylsalicylic
acid (ASA), ASA and clopidogrel) for non-valvular atrial
fibrillation and among subpopulations.
Design: Systematic review and network meta-analysis.
Data sources: A systematic literature search strategy
was designed and carried out using MEDLINE,
EMBASE, the Cochrane Register of Controlled Trials
and the grey literature including the websites of
regulatory agencies and health technology assessment
organisations for trials published in English from 1988
to January 2014.
Eligibility criteria for selecting studies:
Randomised controlled trials were selected for
inclusion if they were published in English, included at
least one antithrombotic treatment and involved
patients with non-valvular atrial fibrillation eligible to
receive anticoagulant therapy.
Results: For stroke or systemic embolism, dabigatran
150 mg and apixaban twice daily were associated with
reductions relative to standard adjusted dose VKA,
whereas low-dose ASA and the combination of
clopidogrel plus low-dose ASA were associated with
increases. Absolute risk reductions ranged from 6
fewer events per 1000 patients treated for dabigatran
150 mg twice daily to 15 more events for clopidogrel
plus ASA. For major bleeding, edoxaban 30 mg daily,
apixaban, edoxaban 60 mg daily and dabigatran
110 mg twice daily were associated with reductions
compared to standard adjusted dose VKA. Absolute
risk reductions with these agents ranged from 18 fewer
per 1000 patients treated each year for edoxaban
30 mg daily to 24 more for medium dose ASA.
Conclusions: Compared with standard adjusted dose
VKA, new oral anticoagulants were associated with
modest reductions in the absolute risk of stroke and
major bleeding. People on antiplatelet drugs
experienced more strokes compared with anticoagulant
drugs without any reduction in bleeding risk. To fully
elucidate the comparative benefits and harms of
antithrombotic agents across the various
subpopulations, rigorously conducted comparative
studies or network meta-regression analyses of patient-
level data are required.
Systematic review registration number:
PROSPERO registry—CRD42012002721.
Strengths and limitations of this study
▪ This network meta-analysis includes data on
edoxaban from the recently published ENGAGE
AF-TIMI 48 trial.
▪ The studies pooled in this meta-analysis include
antiplatelet agents in addition to newer oral antic-
oagulants and standard adjusted dose vitamin K
antagonists.
▪ We present findings on the relative and absolute
scale, and graphically illustrate absolute risks
using icon arrays.
▪ We report detailed a priori subgroup analyses for
stroke or systemic embolism and major bleeding
using data derived from FDA Public Summary
Documents.
▪ Comparisons between antithrombotic treatments
were largely comprised of single, albeit large,
studies.
▪ There is notable heterogeneity and the small
number of studies limits the analyses that can be
conducted to account for heterogeneity in the
absence of patient-level data.
▪ Icon arrays only consider the primary efficacy
and safety endpoints of underlying studies and
do not account for the different clinical conse-
quences associated with each of the outcomes.
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INTRODUCTION
Atrial fibrillation (AF) is a common cardiac arrhythmia
associated with increased morbidity and mortality.1 2
Patients with AF sustain an increased risk of arterial
thromboembolism and stroke, which are associated with
high recurrence and substantial debilitating impact.
Therefore, antithrombotic strategies using anticoagulant
drugs and antiplatelet agents are recommended for
patients with AF presenting with risk factors for stroke.
Antithrombotic therapy is also associated with a risk of
bleeding; therefore, the beneficial effects on stroke pre-
vention should always be compared against a patient’s
risk of major bleeding.1 2
Existing guidelines recommend anticoagulant therapy
for patients at intermediate or high risk of stroke.1 2
Although standard adjusted dose vitamin K antagonist
(VKA) (eg, warfarin) has been the cornerstone treat-
ment for reducing the risk of stroke or systemic embol-
ism (SE) in this population, it is associated with several
drawbacks2 which have prompted the development of
newer oral anticoagulants such as direct thrombin (dabi-
gatran) and Xa (eg, apixaban, edoxaban, rivaroxaban)
inhibitors.1 2 While some of these newer treatment
options have been demonstrated to be efficacious in pre-
venting stroke or SE compared to standard adjusted
dose VKA, the relative efficacy and risk of bleeding of
newer oral anticoagulants, both among themselves and
in comparison to antiplatelet agents, is not clear, espe-
cially in certain subpopulations of patients, for example,
CHADS2 score <2 or ≥2; time in therapeutic range
(TTR) <66% or ≥66%; Age <75 or ≥75 years. Therefore,
the objective of this paper was to compare antithrombo-
tic agents for the prevention of stroke and major bleed-
ing in patients with non-valvular AF and among
subpopulations.
METHODS
The published literature was identified by searching
MEDLINE, MEDLINE In-Process and Other Non-
Indexed Citations. EMBASE, BIOSIS Previews, PubMed
and the Cochrane Central Register of Controlled Trials
were searched through the Ovid interface to identify
English-language clinical articles published from 1988 to
23 January 2014. Regular alerts were also established.
Websites of regulatory agencies, Canadian and major
international health technology assessment agencies,
clinical practice guidelines as well as The Cochrane
Library (2012, Issue 6) and University of York Centre for
Reviews and Dissemination databases were searched.
Complete details of the electronic search strategy,
including any limits used, are reported in online supple-
mentary appendix 1. The protocol was published online
and was registered in the PROSPERO International
Prospective Register of Systematic Reviews (PROSPERO
registry—CRD42012002721).
The population of interest was individuals with non-
valvular AF requiring anticoagulation (including all risk
levels and regardless of any comorbidities). The follow-
ing treatments were included in the review: apixaban,
dabigatran, edoxaban, rivaroxaban, standard adjusted
dose VKA, acetylsalicylic acid (ASA), ASA and clopido-
grel. Numerous outcomes were considered and results
are reported elsewhere3; however, the focus of this publi-
cation is the outcomes of all-cause stroke or SE and
major bleeding as defined by the International Society
on Thrombosis and Haemostasis (ISTH) definition),4
which were the primary efficacy and safety outcomes
used in the newer oral anticoagulant studies.
Active and placebo-controlled randomised controlled
trials (RCTs) were selected for inclusion if they were
published in English, included at least one antithrombo-
tic treatment under review (using pre-specified doses),
reported data for stroke/SE or major bleeding, and
involved patients with non-valvular AF eligible to receive
anticoagulant therapy, regardless of the level of stroke
risk. Trials that included patients with contraindication
to anticoagulant treatment were excluded. VKA trials
were included if the dose was adjusted to a target inter-
national normalised ratio (INR) 2.0–3.0. Any dose of
ASA was considered for inclusion, but ASA dose was
stratified in the analysis as low (≤100 mg daily), medium
(>100 mg to ≤300 mg daily) or high (>300 mg daily). We
only included new oral anticoagulants which had at least
one large phase III study. Three reviewers independently
extracted the data on baseline characteristics, interven-
tion(s) evaluated, including dose, duration and relevant
co-medication, and results for each included article,
using a standardised template. All extracted data were
checked for accuracy by three independent reviewers.
Any disagreements in the assessment of these data were
resolved through discussion until consensus was
reached. Quality assessment of RCTs was also performed
independently by two reviewers using a standardised
table based on major items from the SIGN 50 instru-
ment for internal validity.5 The trial selection process is
presented in a flow chart based on the Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)6 statement (see online supple-
mentary appendix 2).
Bayesian network meta-analyses were conducted using
WinBUGS software (MRC Biostatistics Unit, Cambridge,
UK). A binomial likelihood model7 which accounts for
use of multi-arm trials was used for analyses, given out-
comes were dichotomous and included multi-arm trials.
Trials with zero cells in both arms or nodes, where there
were no events, were excluded from the evidence net-
works because they do not contribute information or
allow interpretable information.7 Both fixed and
random-effects network meta-analyses were conducted,
although the fixed-effects model was chosen for the ref-
erence case analysis, as the evidence network was largely
comprised of single study connections. We modelled
point estimates and 95% credible intervals for OR using
Markov Chain Monte Carlo methods. The absolute risk
difference per 1000 patients treated each year for each
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outcome was also calculated, based on the standard
adjusted dose VKA arm of the Randomised Evaluation
of Long-Term Anti-coagulation Therapy (RE-LY) trial.8
The RE-LY trial8 was selected because it contained data
for both CHADS2 <2 and CHADS2 ≥2 and had
detailed data available from the Food and Drug
Administration (FDA) Public Summary Report.9 We
also assessed the probability that each treatment was
the most efficacious regimen, the second best, the
third best and so on.10 Vague or flat priors, such as N
(0, 1002), were assigned for basic parameters through-
out, although informative priors were considered.11
Assessment of model fit was based on the deviance
information criterion (DIC) and comparison of
residual deviance to number of unconstrained data
points.7 12 To ensure that convergence was reached,
trace plots and the Brooks-Gelman-Rubin statistic were
assessed.13 Three chains were fitted in WinBUGS for
each analysis, with at least 40 000 iterations, and a
burn-in of at least 40 000 iterations. We also qualita-
tively compared the results from our network
meta-analysis with direct pairwise estimates.
Frequentist pairwise meta-analyses were conducted
using R (R Language and Environment for Statistical
Computing, Vienna, Austria) and package meta.14
A key assumption behind network meta-analysis is that
the analysed network is consistent, that is, there is no
conflict between direct and indirect evidence.15 To
assess inconsistency, we compared deviance and DIC sta-
tistics in fitted consistency and inconsistency models.15
We also plotted the posterior mean deviance of the indi-
vidual data points in the inconsistency model against
their posterior mean deviance in the consistency model
to identify any loops where inconsistency was present
(see online supplementary appendix 11).15 Additionally,
the results from our network meta-analysis were qualita-
tively compared with direct frequentist pairwise
estimates.
Network meta-analysis also requires that studies are
sufficiently similar in order to pool their results.16
Available study and patient characteristics were assessed
to ensure similarity and to investigate the potential
impact of heterogeneity on effect estimates. Clinical and
methodological heterogeneity was identified in a
number of areas. The issues identified were similar to
those reported in previous systematic reviews of anti-
coagulant drugs (eg, differences in TTR, CHADS2
score).17 Heterogeneity was assessed by conducting
network meta-analysis with the following pre-specified
subgroup data reported in the individual RCTs: TTR
<66% or ≥66%; CHADS2 score <2 or ≥2; Age <75 or
≥75 years.17 The data to conduct these subgroup ana-
lyses were derived from FDA Public Summary
Documents when not available in the publications.9 18 19
Secondary evidence networks were constructed for each
of the subgroup analyses. The WinBUGS code7 and data
needed to replicate all analyses are available online.
RESULTS
Study characteristics of included studies
The systematic review included 16 individual RCTs
(reported in 32 publications and FDA reports); all evalu-
ated the efficacy and safety of antithrombotic agents:
apixaban (5 mg twice daily), dabigatran (150 or 110 mg
twice daily), edoxaban (30 or 60 mg daily), rivaroxaban
(20 mg daily), standard adjusted dose VKA, ASA (low
dose (<100 mg daily), medium dose (100–300 mg
daily)), or low-dose ASA plus clopidogrel (75 mg daily)
in patients with non-valvular AF. None of the included
studies directly compared one new oral anticoagulant
drug with another (see online supplementary appendix
4). Of the 82 396 randomised patients included in the
primary analysis, five large multicentre trials account for
78 296 patients (96%): ENGAGE AF-TIMI 48 (n=21
105),20 ARISTOTLE (n=18 201),21 RE-LY (n=18 113),8
ROCKET-AF (n=14 264)22 and ACTIVE-W (n=6706).23
Most trials included stroke and SE as a primary efficacy
outcome, while bleeding events were a frequent safety
outcome. Follow-up ranged from 12 weeks to 3.5 years.
All trials published results between 1989 and 2013. The
mean CHADS2 score was reported in eight trials, encom-
passing the vast majority of patients included in the sys-
tematic review. Reported CHADS2 scores were consistent
with a high-risk population (CHADS2 ≥2), with patients
from ROCKET-AF22 showing the highest risk for stroke
(mean CHADS2=3.5).
Mean age across the included trials ranged from 62 to
83 years (see online supplementary appendix 3). All
trials included patients of both gender and had a higher
proportion of male participants in most studies.
However, the proportions of patients with a prior stroke
or TIA varied substantially across the included trials,
ranging from 3% in JAST to 55% in ROCKET-AF.22 The
same observation can be made regarding the propor-
tions of patients with other concomitant conditions, that
is, congestive heart failure, hypertension, diabetes, myo-
cardial infarction and prior VKA experience. TTR was
reported in all but one trial that included a standard
adjusted dose VKA treatment arm. Patient baseline
characteristics are summarised in online supplementary
appendix 3.
The studies were critically appraised individually and
the details are reported elsewhere.3 Overall, there was
substantial variation in study quality. However, large mul-
ticentre trials comparing newer anticoagulants with
standard adjusted dose VKA, such as ENGAGE AF-TIMI
48 (n=21 105), ARISTOTLE (n=18 201), RE-LY
(n=18 113) and ROCKET-AF (n=14 264), which account
for the vast majority of patients included in the system-
atic review, appear to be methodologically rigorous.
Stroke or SE
The evidence network (figure 1) for the primary analysis
was comprised of 12 RCTs representing eight treatments in
addition to placebo/observation (N=82 396). Four RCTs
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(Chung et al,26 PETRO,24 WASPO25 and Yamashita et al27)
were not included in the analysis because they did not
report data for this outcome or had zeros in both arms.
Dabigatran (150 mg twice daily) and apixaban were
associated with reductions in stroke or SE relative to
standard adjusted dose VKA (figure 2). The use of these
two agents led to absolute risk reductions ranging from
4 to 6 fewer events per 1000 patients treated each year.
In contrast, low-dose ASA and the combination of clopi-
dogrel plus low-dose ASA appeared to have a higher risk
of stroke or SE than standard adjusted dose VKA,
leading to an increase in the number of stroke or SE
ranging from 14 to 15 more events per 1000 patients
treated each year (figure 4 and see online supplemen-
tary appendix 6). No differences were detected between
standard adjusted dose VKA and each of the following
interventions: dabigatran (110 mg twice daily), edoxa-
ban (30 mg or 60 mg daily), rivaroxaban and medium-
dose ASA (figure 3).
The estimates of effect derived from the direct pair-
wise comparisons aligned well with those obtained from
the network meta-analysis in direction and magnitude
(see online supplementary appendix 6). Furthermore,
the posterior mean residual deviance (29.41) is close to
the number of unconstrained data points (27), which is
an indication of reasonable model fit. A number of sub-
group analyses and alternative modelling strategies were
conducted on the primary analysis, including adjusting
for CHADS2, TTR and age (table 1). We also conducted
a sensitivity analysis where we included the AVERROES28
and ACTIVE A29 trials (see online supplementary appen-
dix 12). These studies were excluded from the main ana-
lysis because we required patients to be eligible for
anticoagulant therapy, including treatment with a VKA.
The results differed slightly from the reference case (see
online supplementary appendix 12). The primary ana-
lysis was conducted using a fixed-effects model because
the network was comprised of single study connections;
these results were also compared against those obtained
using a random-effects model with informative and
vague priors on the SD and found to be similar in mag-
nitude, although wider credible intervals were observed
(see online supplementary appendix 9).
Major bleeding
The evidence network for the primary analysis for
major bleeding was comprised of 15 RCTs representing
eight treatments in addition to placebo/observation
(N=83 015). The evidence network for major bleeding is
similar to the evidence network for stroke or SE (figure 1)
but includes one extra RCT (WASPO25) comparing
medium-dose ASA with standard adjusted dose VKA, and
two extra RCTs (Chung et al,26 and Yamashita et al27) com-
paring edoxaban with standard adjusted dose VKA (see
online supplementary appendix 5).
Edoxaban 30 mg daily, apixaban, edoxaban 60 mg
daily and dabigatran 110 mg twice daily were associated
with reductions in the risk of major bleeding compared
with standard adjusted dose VKA (figure 2). No differ-
ences for major bleeding were detected between
Figure 1 Evidence network for all-cause stroke or systemic embolism. (Four RCTs, PETRO,24 WASPO25 Chung et al26 and
Yamashita et al,27 were not included in the analysis because they did not report data for this outcome or had zeros in both arms.)
The width of the lines is proportional to the number of randomised controlled trials comparing each pair of treatments, and the
size of each treatment node is proportional to the number of randomised participants (sample size). A dotted line indicates a
three-arm randomised controlled trial and a black node indicates a node included in the analysis but not reported in the main text.
ASA, acetylsalicylic acid; RCT, randomised controlled trial; VKA, vitamin K antagonist.
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standard adjusted dose VKA and each of the remaining
interventions: dabigatran 150 mg twice daily, rivaroxa-
ban, clopidogrel plus low-dose ASA and all ASA dosages
(figure 2). The absolute risk difference of major bleed-
ing relative to standard adjusted dose VKA ranged from
18 fewer to 24 more events per 1000 patients treated per
year (figure 4 and see online supplementary appendix
7). A summary of the results for the Bayesian and direct
pairwise meta-analyses is shown in online supplementary
appendix 7, and Bayesian network meta-analysis results
are represented graphically in figure 2. Complete results
from the Bayesian network meta-analysis for all possible
comparisons are presented in figure 3.
The estimates of effect derived from the direct pair-
wise comparisons aligned well with those obtained from
the network meta-analysis in direction and magnitude
(see online supplementary appendix 7). Furthermore,
the posterior mean residual deviance (38.0) is close to
the number of unconstrained data points (35), which is
an indication of reasonable model fit. A number of sub-
group analyses and alternative modelling strategies were
conducted on the primary analysis (table 1). We also
conducted a sensitivity analysis where we included the
AVERROES28 and ACTIVE A29 trial (see online supple-
mentary appendix 12), as well as analyses using a
random-effects model with vague and informative priors
(see online supplementary appendix 9).
Benefit–harm assessment—stroke or SE versus
major bleeding
Figure 3 summarises the results for all pairwise compari-
sons derived from the Bayesian fixed-effects network
meta-analysis (see online supplementary appendix 9).
Results relative to standard adjusted dose VKA have
been discussed above. For pairwise comparisons among
newer oral anticoagulants for stroke or SE, dabigatran
150 mg twice daily was associated with fewer events
versus dabigatran 110 mg twice daily, edoxaban 30 mg
daily, edoxaban 60 mg daily and rivaroxaban. Apixaban
and rivaroxaban were also associated with fewer events
compared to edoxaban 30 mg daily. There were no dif-
ferences among low-dose ASA, medium-dose ASA, and
clopidogrel plus low-dose ASA. However, low-dose ASA
and the combination of clopidogrel plus low-dose ASA
were associated with increases in stroke or SE compared
to all newer oral anticoagulants. For major bleeding,
apixaban and dabigatran 110 mg twice daily were asso-
ciated with fewer events versus dabigatran 150 mg twice
daily and rivaroxaban. Edoxaban 30 mg daily was asso-
ciated with fewer events than other new oral anticoagu-
lants, while edoxaban 60 mg daily was associated with
fewer events compared with rivaroxaban and clopidogrel
plus low-dose ASA. The risk of major bleeding for apixa-
ban was lower compared to clopidogrel plus low-dose
ASA. There were no differences associated with the ASA
Figure 2 OR for all-cause stroke or systemic embolism (A) and major bleeding (B) in Bayesian network meta-analysis versus
standard adjusted dose VKA. CrI, credible interval; VKA, vitamin K antagonist.
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Figure 4 Icon array illustrating the absolute risks of Stroke or systemic embolism (blue) and major bleeding episodes (red) per
1000 patients treated. (Figures do not reflect uncertainty around effect estimates and there is more uncertainty (ie, wider credible
intervals) for low-dose ASA, medium-dose ASA and clopidogrel plus low dose ASA (see online supplementary appendix 8).
Underlying studies may also double count haemorrhage stroke.)
Figure 3 OR from network meta-analyses for stroke or systemic embolism and major bleeding for all pairwise comparisons.
(Results between individual treatments, especially newer oral anticoagulants, should be interpreted with caution, given the
limitations associated with using a fixed-effects model. See online supplementary appendix 9 for additional details.) ORs for
recurrence of stroke or systemic embolism are below the diagonal (row-defining treatment vs column-defining treatment) and those
for major bleeding are above the diagonal and in blue (column-defining treatment vs row-defining treatment). To obtain ORs for
comparisons in the opposite direction, reciprocals should be taken (eg, the OR for standard dose warfarin compared with apixaban
5 mg twice daily for stroke or systemic embolism is 1/0.78=1.28). Significant results are in bold. VKA, vitamin K antagonist.
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Table 1 Subgroup and sensitivity analyses for stroke or systemic embolism and major bleeding relative to standard adjusted dose VKA, OR±95% credible intervals versus standard adjusted
dose VKA
Treatment
Reference
case—fixed
effect NMA
Subgroup analysis by CHADS2 score Subgroup analysis by age Subgroup analysis by TTR
CHADS2 <2 CHADS2 ≥2 Age <75 years Age ≥75 years TTR <66% TTR ≥66%
Stroke or systemic embolism
Dabigatran 150 mg twice daily 0.66 (0.53, 0.82) 0.61 (0.37, 0.999) 0.66 (0.52, 0.85) 0.63 (0.46, 0.87) 0.66 (0.48, 0.90) 0.54 (0.39, 0.73) 0.81 (0.58, 1.11)
Apixaban 5 mg twice daily 0.78 (0.65, 0.94) 0.86 (0.57, 1.28) 0.78 (0.63, 0.95) 0.85 (0.67, 1.07) 0.71 (0.53, 0.95) 0.79 (0.62, 1.003) 0.79 (0.60, 1.05)
Edoxaban 60 mg daily 0.87 (0.74, 1.02) NA 0.87 (0.74, 1.01) 0.91 (0.73, 1.14) 0.83 (0.66, 1.04) 0.83 (0.65, 1.07) * 0.91 (0.73, 1.13)*
Rivaroxaban 20 mg daily 0.88 (0.74, 1.04) NA 0.88 (0.74, 1.04) 0.95 (0.75, 1.2) 0.80 (0.63, 1.03) 0.81 (0.65, 1.01) 0.72 (0.47, 1.10)
Dabigatran 110 mg twice daily 0.91 (0.74, 1.12) 1.00 (0.64, 1.55) 0.89 (0.71, 1.12) 0.93 (0.7, 1.24) 0.88 (0.66, 1.19) 0.91 (0.69, 1.19) 0.90 (0.66, 1.24)
Edoxaban 30 mg daily 1.14 (0.98, 1.32) NA 1.14 (0.98, 1.32) 1.16 (0.94, 1.44) 1.13 (0.91, 1.40) 1.01 (0.80, 1.28)* 1.24 (1.01, 1.24)*
Medium-dose ASA (>100 mg and
≤300 mg daily)
1.35 (0.74, 2.47) 1.97 (0.63, 6.73)† NA NA NA NA NA
Low-dose ASA (≤100 mg daily) 1.87 (1.26, 2.8) 2.20 (1.18, 4.25) 2.10 (0.91, 5.15) ‡ NA 2.04 (1.33, 3.20) NA NA
Clopidogrel 75 mg daily and
Low-dose aspirin (≤100 mg daily)
1.93 (1.42, 2.64) 3.16 (1.39, 8.22) 1.15 (0.84, 1.57) NA NA 1.52 (0.96, 2.45) 2.40 (1.59, 3.71)
Major bleeding
Edoxaban 30 mg daily 0.46 (0.4, 0.54) NA 0.46 (0.4, 0.54) 0.50 (0.41, 0.61)§ 0.51 (0.41–0.62)§ 0.45 (0.35, 0.58)*§ 0.51 (0.43, 0.61)*§
Apixaban 5 mg twice daily 0.69 (0.6, 0.80) 0.59 (0.44, 0.78) 0.73 (0.62, 0.87) 0.73 (0.6, 0.89) 0.65 (0.52, 0.80) 0.57 (0.45, 0.71) 0.81 (0.67, 0.98)
Edoxaban 60 mg daily 0.79 (0.69, 0.9) NA 0.79 (0.69, 0.90) 0.74 (0.62–0.90)§ 0.82 (0.68–0.98)§ 0.69 (0.55, 0.87) ast;§ 0.83 (0.70, 0.97)*§
Dabigatran 110 mg twice daily 0.80 (0.69, 0.93) 0.65 (0.47, 0.89) 0.86 (0.73, 1.02) 0.62 (0.49, 0.77) 1.02 (0.84, 1.25) 0.74 (0.61, 0.91) 0.86 (0.69, 1.06)
Dabigatran 150 mg twice daily 0.93 (0.81, 1.08) 0.77 (0.57, 1.04) 1.01 (0.86, 1.19) 0.70 (0.56, 0.86) 1.19 (0.98, 1.45) 0.76 (0.62, 0.94) 1.15 (0.94, 1.40)
Rivaroxaban 20 mg daily 1.03 (0.89, 1.19) NA 1.03 (0.89, 1.19) 0.93 (0.76, 1.13) 1.15 (0.93, 1.41) 0.92 (0.77, 1.10) 1.30 (1.01, 1.69)
Low-dose ASA (≤100 mg daily) 1.05 (0.6, 1.87) 0.83 (0.42, 1.64) 1.60 (0.55, 5.02) ‡ NA 1.01 (0.57, 1.78) NA NA
Clopidogrel 75 mg daily and
low-dose aspirin (≤100 mg daily)
1.10 (0.83, 1.47) 1.51 (0.89, 2.61) 0.97 (0.69, 1.36)¶ NA NA 0.66 (0.42, 1.02) 1.66 (1.12, 2.47)
Medium-dose ASA (>100 mg and
≤300 mg daily)
1.79 (0.63, 5.67) 1.48 (0.11, 19.07)† NA NA NA NA NA
Significant results are in bold.
*Data provided from ENGAGE AF-TIMI 4820 use TTR >60%.
†Results may be slightly biased against medium-dose ASA. Based on study level results from CAFA and JAST studies. Although these studies consisted primarily of low-risk populations, some
patients may have CHADS2 scores greater than 2.
‡Results may be slightly biased against LDASA. Derived from the BAFTA study where CHADS2 subgroup data were stratified by CHADS2 1–2 (vs 0–1) and CHADS2 3–6 (vs 2–6).
§Based on overall time period where overall time period was defined as first dose to the last dose plus 3 days.
¶Estimated from the subgroup study by Healey et al (2008).29a
ASA, acetylsalicylic acid; NA, not available; NMA, network meta-analysis; TTR, time in therapeutic range; VKA, vitamin K antagonist.
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treatments, both for comparisons among themselves and
compared to the anticoagulant treatments.
Figure 4 plots the absolute risk for stroke or SE and
major bleeding per 1000 treated for the 10 treatments
analysed. Data in figure 4 were obtained from the results
presented in online supplementary appendix 6 and
7. Examination of the data in figure 4 suggests that the
balance of benefits and harms of the new oral anticoagu-
lants for stroke or SE and major bleeding is positive com-
pared to standard adjusted dose VKA (decrease in stroke
or SE and/or major bleeding) and largely similar among
one another. Comparison of all anticoagulant treatment
(including standard adjusted dose VKA) to ASA or ASA
in combination with clopidogrel indicates that whereas
the new oral anticoagulants decrease the risk of stroke or
SE and major bleeding, ASA has a less favourable balance
of benefits and harms, that is, fails to minimise the risk of
stroke or SE and/or major bleeding.
DISCUSSION
We identified 16 RCTs comparing antithrombotic agents
for the prevention of all cause stroke or SE and major
bleeding in patients with AF. To the best of our knowl-
edge, this is the most up-to-date systematic review and
network meta-analysis30–34 to synthesise the available ben-
efits and harms on newer oral anticoagulants, standard
adjusted dose VKA and antiplatelet agents for the preven-
tion of stroke and major bleeding in patients with non-
valvular AF (see online supplementary appendix 13).
Harenberg et al30 recently summarised the published
indirect comparisons and network meta-analyses evaluat-
ing newer oral anticoagulants for AF and an earlier
unpublished version of our analysis17 was considered to
be among the most comprehensive analyses at that
time.30 This network meta-analysis expands on that
unpublished report.17 Overall, our findings align with
those reported in previously published network
meta-analyses30 31 33; however, unlike previous analyses,30
we include recently published edoxaban data,20 and also
include antiplatelet agents. We also present detailed evi-
dence networks35 to illustrate the body of evidence for
each outcome; report analysis using multiple statistical
models (see online supplementary appendix 9); report
detailed a priori subgroup analyses for each outcome
using data derived from FDA Public Summary
Documents9 18; present findings on the relative and abso-
lute scale,36 37 and graphically illustrate results using icon
arrays. Our network meta-analysis was registered in
PROSPERO, and also adheres to PRISMA reporting stan-
dards (see online supplementary appendix 10). It also
differs from a recently published traditional meta-analysis
by Ruff et al,32 given that we report the comparison of
newer oral anticoagulants versus each other and also
include comparisons with antiplatelet agents.
For stroke or SE, dabigatran 150 mg and apixaban
twice daily were associated with reductions in stroke or
SE relative to standard adjusted dose VKA. In contrast,
low-dose ASA and the combination of clopidogrel plus
low-dose ASA that appeared were associated with
increases in stroke or SE relative to standard adjusted
dose VKA. No differences were detected between stand-
ard adjusted dose VKA and each of the following inter-
ventions: dabigatran 110 mg twice daily, edoxaban 30
and 60 mg daily, rivaroxaban, medium-dose ASA and no
treatment/placebo. The absolute risk reduction of
stroke or SE relative to standard adjusted dose VKA
ranged from 6 fewer to 15 more events per 1000 patients
treated per year, with dabigatran 150 mg twice daily
yielding the largest absolute risk reduction and clopido-
grel plus low-dose ASA the largest absolute risk increase.
For major bleeding, edoxaban 30 mg daily, apixaban,
edoxaban 60 mg daily and dabigatran 110 mg twice daily
were associated with a decreased risk of major bleeding
relative to standard adjusted dose VKA. No differences
for major bleeding were detected between standard
adjusted dose VKA and each of the remaining interven-
tions: dabigatran 150 mg twice daily, rivaroxaban, clopi-
dogrel plus low-dose ASA and all ASA dosages. The
absolute risk difference of major bleeding relative to
standard adjusted dose VKA ranged from 18 fewer to 24
more events per 1000 patients treated, with edoxaban
30 mg daily yielding the largest absolute risk reduction
and medium-dose ASA the largest absolute risk increase.
Results of network meta-analyses reflect the relative effi-
cacy and safety profile of antiplatelet and anticoagulant
drugs as documented by large clinical trials. Thus, inter-
national guidelines1 2 for prevention of stroke in patients
with AF also recommended oral anticoagulation over
antiplatelet therapy as the latter had only modest pro-
tective effects. With respect to the new oral anticoagu-
lants, none of the guidelines has given a
recommendation to prefer one of the new oral anticoa-
gulants over another.1 2
Network meta-analysis involves pooling of trials. We
observed variability across studies included in the evi-
dence network in terms of CHADS2, age and TTR (see
online supplementary appendices 3 and 4). For
example, patients using rivaroxaban had a higher risk of
stroke because ROCKET-AF22 included patients with
CHADS2 ≥2. As such, we conducted subgroup analysis
to adjust for differences in patient and study-level
characteristics. We derived data for subgroup analyses
from FDA Public Summary documents,9 18 19 which
enhanced our ability to account for variability across
studies (eg, use intention to treat population for rivarox-
aban versus per-protocol as-treated population reported
in publication22). Results from these subgroup analyses
differed slightly from those reported in the primary ana-
lysis, indicating that there may be differences in the ben-
efits and harms across subgroups. This becomes more
apparent when subgroup analyses are reported on the
absolute scale.3 It is unclear whether the absolute risk
reductions associated with these differences translate
into clinically meaningful benefits in practice, especially
in subpopulations of patients with a lower baseline risk
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of stroke or SE. To fully elucidate the comparative bene-
fits and harms of antithrombotic agents across the
various subpopulations, rigorously conducted compara-
tive studies38 39 or network meta-regression analyses of
patient-level data40 are required.
There are several limitations with the analysis we
employed. First, there is notable heterogeneity in
patients and study characteristics (see online supplemen-
tary appendices 3 and 4). However, the small number of
studies limits the analyses that can be conducted to
account for heterogeneity in the absence of patient-level
data. Second, there is insufficient subgroup data avail-
able for other outcomes reported in the RCTs included.
As a consequence, detailed analysis was limited to two
outcomes—stroke and SE and major bleeding. Third,
we reported the results from the fixed-effects model in
the main text. We felt that this was appropriate as the
nodes in evidence networks are connected largely by
single studies. Effect estimates derived from the
fixed-effects model aligned more closely with the direct
estimates. Reporting results from the fixed-effects model
in the main text most likely biases results in favour of
the new oral anticoagulants, as treatments that achieved
statistically significant results in the primary RCTs
retained statistically significant findings when using
the fixed-effects model, but not always when using the
random-effects model due to the prior11 on the
between-study variance. Nevertheless, the results from
the random-effects model have also been reported in
online supplementary appendix 9, along with a detailed
discussion around the limitations in using the
fixed-effects model. Fourth, the absolute risk reduction
for the network meta-analysis was calculated using the
event rate in the standard adjusted dose VKA arm of the
RE-LY study. The RE-LY trial was selected because it con-
tained data for both CHADS2 <2 and CHADS2 ≥2 and
had detailed data made publicly available following an
FDA review of dabigatran. Use of a different study (eg,
ARISTOTLE) for baseline event rate data is unlikely to
change the results substantially, given that the event
rates in standard adjusted dose VKA arms were similar
across studies. Fifth, we present findings using graphics
that have been largely applied in the network
meta-analysis literature,41 such as a table with OR for all
pairwise comparisons. This method of presenting find-
ings on the relative scale is problematic when you are
conducting assessments to compare the balance of bene-
fits and harms, which need to be standardised. As such,
we also provided results in absolute terms. We report
our findings using icon arrays, although it should be
noted that these results do not account for the utility
values based on patient preferences for each of the out-
comes;42 43 nor do they reflect uncertainty, although we
report absolute reductions on the risk benefit plane
reflecting uncertainty in online supplementary appendix
8. There are other methods available that can incorpor-
ate patient preferences for outcomes.42 43 Further, esti-
mates of benefits and harms with several of the
therapies (eg, rivaroxaban) come from one trial, and
thus such data are not particularly robust. Further
research is needed that compares the balance of benefits
and harms using other research methodologies, incorp-
orating other relevant outcomes, patient preferences for
each of the outcomes42 43 and additional studies when
they become available. Finally, haemorrhagic stroke is
also considered a major bleed in underlying studies.
Accordingly, we may have double counted haemorrhage
stroke in this analysis. Unfortunately, we are not able to
account for this issue in all included studies.
Nonetheless, it is important to note this limitation and
highlight that this potentially biases results in favour of
newer oral anticoagulants, given that these agents were
associated with reductions in these events.
CONCLUSIONS
Compared with standard adjusted dose VKA, dabigatran
150 mg and apixaban twice daily were associated with
reductions in the incidence of stroke or SE in patients
with AF, whereas low-dose ASA and the combination of
clopidogrel plus low-dose ASA increased the risk relative
to standard adjusted dose VKA at preventing stroke or
SE. Edoxaban 30 mg daily, apixaban, edoxaban 60 mg
daily and dabigatran 110 mg twice daily were associated
with reduced risk in major bleeding compared with
standard adjusted dose VKA. Although the results of the
current review revealed that there were differences in
stroke or SE and major bleeding among antithrombotic
agents in the management of patients with AF in relative
terms, it is unclear whether the absolute risk reductions
associated with these differences translate into clinically
meaningful benefits in practice, especially in subpopula-
tions of patients with a lower baseline risk of stroke or SE.
Rigorously conducted comparative studies or network
meta-regression analyses of patient-level data are required
to fully elucidate the comparative benefits and harms of
antithrombotic agents across the various subpopulations.
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